^
Association details:
| Biomarker: | EGFR D770 delinsGY |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Vizimpro (dacomitinib) (pan-HER inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib
Published date:
09/13/2023
Excerpt:
Both EGFR exon 20 insertional mutation (Ex20ins) and HER2 Ex20ins demonstrated significant internal heterogeneity in response to dacomitinib, among which specific subtypes (including EGFR D770delinsGY, A763_Y764insFQEA, and HER2 M774delinsWLV) were highly sensitive. Other uncommon EGFR mutations including 18del and L747P have also been shown responsive to dacomitinib.
DOI:
10.21037/tcr-23-95
